Trailing-twelve-month (TTM) revenue is $30.68 Million with a year-over-year growth of +8.49%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $5,506,122 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $7,625,999 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-30 |
| Q1 FY2026Period ended 2026-03-31 | $10,357,295 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $7,186,113 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $30,675,529 |
Current P/S: $90,196,586 market capitalization ÷ $30,675,529 TTM revenue = 2.94x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $7.19M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T22:41:56.706Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2021-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-12-31 · USD |
|---|---|
| FirstDefenseProductLineMember | $19M |
| OtherAnimalHealthMember | $309,877 |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD |
|---|---|---|---|
| OtherStatesMember | $3M | N/A | N/A |
| UNITED STATES | $17M | $16M | $23M |
$30.68M
$30.68 Million
+8.49%
vs. $28.27M a year ago (TTM)
+13.74%
5 Year compound annual growth rate
1 Year
+8.49%
3 Year
+25.05%
5 Year
+13.74%
10 Year
+11.29%
15 Year
+13.17%
20 Year
+9.73%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $27.64M | +$1.15M | +4.34% |
| 2024 | $26.49M | +$9.02M | +51.64% |
| 2023 | $17.47M | ($1.10M) | (5.90%) |
| 2022 | $18.57M | ($674,969) | (3.51%) |
| 2021 | $19.24M | +$3.90M | +25.43% |
| 2020 |
TTM Growth
+8.49%
3-Year CAGR
+25.05%
5-Year CAGR
+13.74%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T22:41:56.706Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $15.34M |
| +$1.62M |
| +11.80% |
| 2019 | $13.72M | +$2.74M | +24.91% |
| 2018 | $10.99M | +$555,000 | +5.32% |
| 2017 | $10.43M | +$887,039 | +9.29% |
| 2016 | $9.54M | ($684,728) | (6.69%) |
